Type-specific immunity in pseudomonas diseases.

Abstract Sera from normal subjects and from patients with pseudomonas infections were studied for the presence of precipitins and hemagglutinins to the purified lipopolysaccharide antigens of the seven Fisher-Devlin-Gnabasik pseudomonas immunotypes. Sera were also tested for their capacity to protect mice against challenge by these strains. Sera from normal subjects did not contain precipitins and had hemagglutinin titers after mercaptoethanol treatment of less than 64 against all of the seven purified antigens. Sera from 15 of 22 patients with pseudomonas infections contained precipitins to one or more antigens. Eight sera contained precipitins to only one antigen. Sera of 11 patients with pseudomonas infections had hemagglutinin titers after mercaptoethanol treatment of greater than 64, in each instance to only 1 antigen. Sera with hemagglutinin titers of greater than 64 either before or after mercaptoethanol treatment and with detectable precipitins produced greater mouse protection than sera with hemagglutinin titers of less than 64 and negative precipitins. Most individual sera had higher mouse protective titers against strains to which the hemagglutinin titer was higher. Mercaptoethanol-treated sera from all patients tested protected mice in higher titer of sera against strains to which the hemagglutinin titer after mercaptoethanol treatment was greater than 64. The majority of sera tested also had higher mouse protective titers against strains to which precipitins were present. Acquired immunity to pseudomonas infection in man, as determined by these studies, is largely type-specific.

[1]  D. Watson,et al.  Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. , 1971, Nature: New biology.

[2]  J. G. Michael,et al.  Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosa , 1970, Infection and immunity.

[3]  L. Young,et al.  Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections , 1970, Infection and immunity.

[4]  M. Artenstein,et al.  Prevention of meningococcal disease by group C polysaccharide vaccine. , 1970, The New England journal of medicine.

[5]  J. G. Crowder,et al.  A serologic response in human pseudomonas infection. , 1970, The Journal of laboratory and clinical medicine.

[6]  W. Altemeier,et al.  Prevention of invasive pseudomonas infection in burns with a new vaccine. , 1969, Archives of surgery.

[7]  H. Devlin,et al.  New Immunotype Schema for Pseudomonas aeruginosa Based on Protective Antigens , 1969, Journal of bacteriology.

[8]  J. A. Bass,et al.  Immunization against Pseudomonas aeruginosa. I. Induction of protection by an alcohol-precipitated fraction from the slime layer. , 1967, The Journal of infectious diseases.

[9]  K. Markley.  Immunotherapy of Pseudomonas infections. , 1967, Annals of internal medicine.

[10]  J. Alexander,et al.  Studies on the isolation of an infection-protective antigen from Psudomonas aeruginosa. , 1966, Surgery, gynecology & obstetrics.

[11]  R. Millican,et al.  Susceptibility of Burned Mice to Pseudomonas aeruginosa and Protection by Vaccination , 1966, Annals of surgery.

[12]  I. Feller,et al.  USE OF VACCINE AND HYPERIMMUNE SERUM FOR PROTECTION AGAINST PSEUDOMONAS SEPTICEMIA. , 1964, The Journal of trauma.

[13]  G. Rinker,et al.  QUANTITATIVE STUDIES OF ANTIBODIES AGAINST JENSEN'S ANTIGEN A IN HUMAN SERA. , 1964, Antimicrobial agents and chemotherapy.

[14]  E. Lowbury,et al.  Immunity and antibody to Pseudomonas pyocyanea in rabbits. , 1953, The Journal of pathology and bacteriology.

[15]  M. Heidelberger,et al.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES , 1945, The Journal of experimental medicine.